Navigation Links
Champions Oncology Reports Full Year 2011 Financial Results
Date:7/15/2011

BALTIMORE, July 15, 2011 /PRNewswire/ -- Champions Oncology, Inc., formerly Champions Biotechnology, Inc., (OTC: CSBR):

Highlights:

  • Company completes $9.4 million financing during 2011
  • Revenue growth of 41% to $6.9 million
  • Net loss of $3.8 million; excluding stock based compensation a net loss of $0.7 million*
  • Net loss of ($0.10) per share; net loss excluding stock-based compensation of ($0.02) per share*
  • Cash of $10.5 million at year end

  • Annual 2011 Financial Results:For its fiscal year 2011, Champions generated revenue of $6.9 million, an increase of $2 million or 41%, compared to fiscal year 2010.  

    Champions also reported a net loss of $3.8 million, or ($0.10) per share, compared to a net loss of $2.9 million, or ($0.09) per share, in the corresponding prior year.

    However, excluding stock based compensation* of $3.1 million, Champions recognized net loss of $0.7 million, or ($0.02) per share for 2011 compared to a net loss of $2.3 million excluding stock based compensation* of $0.6 million, or ($0.07) per share for 2010.

    Services RevenuesTotal revenues for fiscal 2011 were $6.9 million compared to $4.9 million for fiscal 2010, an increase of $2.0 million, or 41%.  Revenues from Personalized Oncology Solutions, ("POS"), were $3.4 million compared to $3.2 million in the prior year, an increase of $0.2 million, or 6%. Revenues from Translational Oncology Solutions, ("TOS"), previously referred to as Preclinical eValuation services, were $3.5 million for 2011 as the compared to $1.7 million in the prior year, an increase of $1.8 million, or 108%.

    Costs of POS for the fiscal year 2011 and 2010 were $1.6 million and $1.1 million, respectively, an increase of $0.5 million, or 44%.  The increase in costs for POS was due to the increased volume of POS business.  For the fiscal year 2011 and 2010, gross margins fo
    '/>"/>

    SOURCE Champions Oncology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
    2. Champions Biotechnology Changes Name to Champions Oncology
    3. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
    4. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
    5. Champions Biotechnology Reports Additions to its Management Team
    6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
    7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
    8. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
    9. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
    10. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
    11. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
    (Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
    (Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
    Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
    ... 2 Randomized Study Under Consideration, ROCKVILLE, Md., ... a clinical-stage pharmaceutical company developing,therapeutics for the treatment ... has met the primary endpoint for the efficacy ... MKC-1 in combination with pemetrexed,(Alimta(R)) in non-small cell ...
    ... NANJING, China, Nov. 10 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group ... supplier of branded generic,pharmaceuticals and innovative anti-cancer pharmaceuticals ... participation in the Morgan,Stanley 7th Annual Asia Pacific ... Mandarin Oriental Singapore on November 11-13, 2008., ...
    ... Partners will provide partnership for identifying expansion and investment opportunities. ... ... (PRWEB) November 10, 2008 -- World Trade Center Dulles Airport ... seeking to access global markets, today announced its business launch ...
    Cached Biology Technology:EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 2EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 3Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008 2Former NASDAQ International President Among Execs Launching Firm to Access Global Markets 2Former NASDAQ International President Among Execs Launching Firm to Access Global Markets 3
    (Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
    (Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in India 2015-2019" ... major trend emerging in this market is the adoption ... than one characteristic of an individual for verification and ...
    (Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for a ... for this $50 million capital project is part of a ... The medical education building will be located ... adjacent to 525@vine in Wake Forest Innovation Quarter. Construction will ...
    Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
    ... oyster native to the West Coast could face a double ... research from the University of California, Davis, Bodega Marine Laboratory. ... Proceedings of the Royal Society B . Invasive snails ... snails were raised under ocean conditions forecast for the end ...
    ... Minn. , Jan. 15, 2014 MedNet Solutions ... study management systems, is pleased to announce that the latest ... released to the iMedNet user community.  iMedNet ... eClinical platform ideally suited to Sponsors and CROs wanting to ...
    ... news release is available in German . ... economists and politicians usually call a win-win situation: a relationship between ... acacia plants and the ants that live on them is an ... of food bodies and nectar as well as hollow thorns which ...
    Cached Biology News:Acidification, predators pose double threat to oysters 2MedNet Solutions Announces Latest Release Of Its Innovative iMedNet EDC eClinical Solution 2Ants protect acacia plants against pathogens 2Ants protect acacia plants against pathogens 3
    Biotin d anti-mouse Tim-1...
    Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
    Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
    Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
    Biology Products: